CHAPTER 5 114 Clinicopathological characteristics of the study cohort are shown in Table 1. Mean patient age in the study population was 65 years. Most patients presented preoperatively with lowgrade (1-2) EC and endometrioid histology, 71.4% and 89.4% respectively. Pre-operative IHC expression of p53-abn was present in 112 (14.7%), L1CAM+ in 79 (10.4%) and ER/ PR- in 151 (19.8%) patients. IHC staining was unsuccessful in N=67 cases for p53, N=19 for L1CAM, N=1 for ER and N=6 for PR. Lymphadenectomy was performed in 493 (64.6%) patients of whom 53 (10.7%) patients had LNM (N1). Adjuvant treatment was administered in 347 (45.6%) patients, of which 81.6% received radiotherapy (RT). A total of 105 (13.8%) patients developed recurrent EC disease and 102 (13.4%) patients died of whom 61 (59.8%) due to EC. Stratification of the study cohort according to the ESMO-ESGO-ESTRO risk classification is shown in Table 1. A total of 169 (22.1%) EC patients were classified as ‘high’ risk. Immunohistochemical expression in relation to the ESMO-ESGO-ESTRO risk classification In Figure 1 abnormal IHC expression of p53, L1CAM, ER and PR is shown in relation to the ESMO-ESGO-ESTRO risk classification groups. Increased abnormal IHC expression was related to higher risk classification groups (P<0.001), with the highest frequency of p53abn, L1CAM+, ER- or PR- in the ESMO-ESGO-ESTRO ‘high and advanced/metastatic’ subgroups. Table 1. Baseline clinicopathological characteristics of study cohort Total N=763 Patient characteristics Age (years) 65.2 ± 10.2 BMI (kg/m2) 29.9 ± 6.7 Preoperative histology Tumor grade 1-2 545 (71.4) 3 109 (14.4) Not classified 108 (14.2) Histology Endometrioid 682 (89.4) Non-endometrioid 39 (5.1) Not specified 42 (5.5) Biomarker expression p53-abnormal 112 (14.7) L1CAM positive 79 (10.4) ER/PR negative 151 (19.8)
RkJQdWJsaXNoZXIy MTk4NDMw